J44
Conditions
Interventions
Group 1: The study aims to demonstrate the effectiveness of HP-NIV-MER based on the analysis of retrospective and prospective routine data. Patients with COPD are treated with HP-NIV-MER at our hospit
Sponsors
Thoraxklinik Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Chronic obstructive pulmonary disease Chronic hypercapnic respiratory failure HP-NIV-MER
Exclusion criteria
Exclusion criteria: Lung and thoracic diseases others than COPD Severe obesity (BMI greater than 35 kg/m2) Severe heart failure, unstable angina, or severe arrhythmias Malignant underlying or concomitant disease Inability to attend the first follow-up after approximately 3 months Acute hypercapnia with acidosis and/or aeCOPD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ?pCO2 of patients at the first follow-up after approximately 3 months (compared to pCO2 at NIV-initiation) | — |
Secondary
| Measure | Time frame |
|---|---|
| ?S3-NIV at the first follow-up after approximately 3 months (compared to the S3-NIV after initial initiation) S3 NIV on the day of discharge after NIV-initiation Average respiratory rate after NIV-initiation Reported side effects at the first follow-up examination after approx. 3 months Average usage time at the first follow-up examination after approx. 3 months Therapy discontinuations at the first follow-up examination after approx. 3 months Ventilation settings at discharge after NIV-initiation Detect predictors of success and failure of HP NIV-MER, if statistically meaningful Average respiratory rate at the first follow-up examination after approximately 3 months Air leaks at the first follow-up examination after approximately 3 months | — |
Countries
Germany
Contacts
Public ContactBenjamin Neetz
Thoraxklinik Heidelberg
Outcome results
None listed